Market Place
Sourcing Support
Jasper Doses First Patient In Briquilimab Asthma Study ETESIAN
02 Dec 2024 //
GLOBENEWSWIRE
Jasper Therapeutics to Participate at Upcoming Investor Conferences
13 Nov 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Q3 2024 Financial Results & Update
07 Nov 2024 //
GLOBENEWSWIRE
Jasper Therapeutics To Present Briquilimab Data At ACAAI Meeting
24 Oct 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Expands Clinical Program in Urticaria
23 Oct 2024 //
GLOBENEWSWIRE
Jasper Reports Data from Study of Briquilimab in Chronic Urticaria
14 Oct 2024 //
GLOBENEWSWIRE
Jasper Gets Health Canada Clearance For Briquilimab Study
10 Sep 2024 //
GLOBENEWSWIRE
Jasper Therapeutics To Present At September Investor Events
04 Sep 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Reports Q2 2024 Results And Recent Developments
13 Aug 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Appoints Svetlana Lucas To Board
19 Jun 2024 //
GLOBENEWSWIRE
Jasper Therapeutics To Present At Oppenheimer Novel Targets In Immunology Summit
17 Jun 2024 //
GLOBENEWSWIRE
Jasper Presents Preclinical Briquilimab Data At EHA 2024
14 Jun 2024 //
GLOBENEWSWIRE
Jasper To Present Briquilimab Data At EAACI 2024
30 May 2024 //
GLOBENEWSWIRE
Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Reports Q1 2024 Results, Corporate Developments
14 May 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
13 May 2024 //
GLOBENEWSWIRE
Jasper Therapeutics to Present at Upcoming Investor Conferences in May
06 May 2024 //
GLOBENEWSWIRE
Jasper to Present at the 23rd Annual Needham Virtual Healthcare Conference
02 Apr 2024 //
GLOBENEWSWIRE
Jasper Therapeutics to Participate in the H.C. Virtual Conference
21 Mar 2024 //
GLOBENEWSWIRE
Jasper Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT
19 Mar 2024 //
GLOBENEWSWIRE
New Positive Data Presented on Briquilimab Conditioning in Fanconi Anemia
15 Mar 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Reports Fiscal 2023 Financial Results
04 Mar 2024 //
GLOBENEWSWIRE
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
26 Feb 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at AAAAI
23 Feb 2024 //
GLOBENEWSWIRE
Jasper to Present at the Oppenheimer 34th Annual Healthcare Conference
07 Feb 2024 //
GLOBENEWSWIRE
Jasper Announces Pricing of $50 Million Underwritten Offering of Common Stock
06 Feb 2024 //
GLOBENEWSWIRE
Jasper Announces Preclinical Data Presentations at the AAAAI Annual Meeting
05 Feb 2024 //
GLOBENEWSWIRE
Jasper Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Jasper Therapeutics Highlights Recent Accomplishments & Key Upcoming Milestones
05 Jan 2024 //
GLOBENEWSWIRE
Jasper Therapeutics, Inc. Announces Reverse Stock Split
02 Jan 2024 //
GLOBENEWSWIRE
Jaspe Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Dec 2023 //
GLOBENEWSWIRE
Jasper Presents Positive Final Results from Phase 1 Study of Briquilimab
10 Dec 2023 //
GLOBENEWSWIRE
Jasper Announces First Patient Dosed in Phase 1b/2a Study of Briquilimab
30 Nov 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Jasper Therapeutics to Participate at Upcoming Medical and Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
Jasper Announces Presentation of Positive Results from Phase 1 of Briquilimab
02 Nov 2023 //
GLOBENEWSWIRE
Jasper Therapeutics to Host Key Opinion Leader Webinar
09 Oct 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Appoints Herb Cross as Chief Financial Officer
25 Sep 2023 //
GLOBENEWSWIRE
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning
21 Sep 2023 //
GLOBENEWSWIRE
Jasper to Present at the Cantor Fitzgerald 2023 Global Healthcare Conference
15 Sep 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Jasper Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Aug 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Strengthens Management Team with Key Appointments
02 Aug 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Enhances Management Team
02 Aug 2023 //
CONTRACT PHARMA
Jasper doses first patient in trial of myelodysplastic syndrome therapy
23 Jun 2023 //
CLINICAL TRIALS ARENA
Jasper Therapeutics Announces First Patient Dosed in a Ph1 Trial of Briquilimab
22 Jun 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
20 Jun 2023 //
GLOBENEWSWIRE
Jasper Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer
13 Jun 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Reports First Quarter 2023 Financial Results
12 May 2023 //
GLOBENEWSWIRE
Jasper Announces Appointment of Stephen J. Galli, M.D. to SAD
10 May 2023 //
GLOBENEWSWIRE
Jasper Announces Appointment of Matthew Ford as Vice President, Human Resources
13 Apr 2023 //
GLOBENEWSWIRE
Jasper Appoints David Hinds as Senior Vice President, Development Operations
10 Apr 2023 //
GLOBENEWSWIRE
Jasper Therapeutics to Present at Cantor Fitzgerald The Future of Oncology
31 Mar 2023 //
GLOBENEWSWIRE
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting CMO
23 Mar 2023 //
GLOBENEWSWIRE
Jasper Therapeutics to Present at Upcoming Conferences
09 Mar 2023 //
GLOBENEWSWIRE
Jasper Announces Data from Investigator-Sponsored Study of Briquilimab
17 Feb 2023 //
GLOBENEWSWIRE
Jasper Appoints Industry Veteran Vishal Kapoor to its Board of Directors
17 Feb 2023 //
GLOBENEWSWIRE
Jasper Announces Positive Data from Study of Briquilimab in Sickle Cell Disease
16 Feb 2023 //
GLOBENEWSWIRE
Jasper Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 Feb 2023 //
GLOBENEWSWIRE
Jasper to Host Investor Conference Call and Webcast on January 31, 2023
30 Jan 2023 //
GLOBENEWSWIRE
